Uribe M, Bosques F, Marín E, Cervera E, Gil S, Luis Poo J, Garcia Compeán D, Santoyo R, Huerta E, García-Ramos G, Cadena M, Merikansky A, Robledo J, Cortés M, Guevara A, López N, Aguilar A, Alejandra Ochoa E
Departamento de Gastroenterología Instituto Nacional de la Nutrición "Salvador Zubirán", Vasco de Quiroga No. 15, Tlalpan, México 14000, DF.
Rev Invest Clin. 1990 Jul;42 Suppl:149-54.
To investigate the therapeutic efficacy of sodium benzoate (SB) in a cirrotic population with chronic portal systemic encepalopathy (PSE), we performed a double blind, randomised, multicentric, clinical trial, comparing SB versus a standard therapy of lactitol (LA). To perform the study blind, syrups containing the two drugs were prepared. To date 27 patients have been studied. Of these, 12 received SB (5.6 g/day) and 15 received LA (29 g/day). Standard PSE parameters were assessed and hippurate urinary excretion was measured before and after the trial. For the SB group, basal and final PSE index were 0.39 +/- 0.16 and 0.17 +/- 0.1 respectively (p < 0.001). The Group on LA had a PSE index of 0.40 + 0.1 and 0.23 +/- 0.18 (basal and final respectively) (p < 0.001). The final hippurate excretion for SB group was 2498.9 mg/24 h. The hippurate excretion for the LA group suffer no changes (traces). No serious side effects were observed with either therapy. We suggested that SB is a safe, efficacious and comfortable alternate treatment for PSE.
为研究苯甲酸钠（SB）对患有慢性门体性脑病（PSE）的肝硬化患者的治疗效果，我们进行了一项双盲、随机、多中心临床试验，比较SB与乳果糖（LA）标准疗法的疗效。为使研究保持盲态，制备了含有这两种药物的糖浆。迄今为止，已对27例患者进行了研究。其中，12例接受SB（5.6克/天），15例接受LA（29克/天）。在试验前后评估了标准PSE参数并测量了马尿酸盐尿排泄量。SB组的基础和最终PSE指数分别为0.39±0.16和0.17±0.1（p<0.001）。LA组的PSE指数分别为0.40±0.1和0.23±0.18（基础和最终）（p<0.001）。SB组的最终马尿酸盐排泄量为2498.9毫克/24小时。LA组的马尿酸盐排泄量无变化（微量）。两种疗法均未观察到严重副作用。我们认为SB是一种安全、有效且舒适的PSE替代治疗方法。
